Loading…
Loading…
SANTA ANA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigational program, troculeucel, at the 2026 BIOCHINA Global Forum, taking place July 9–10, 2026, in Seoul, South Korea.
SANTA ANA, Calif. , July 02, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y.
New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease.
SANTA ANA, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that it will present data on its lead investigational program, troculeucel, at the 8th Annual Neuroimmunology Drug Development Summit being held April 14-16, 2026, in Boston, Massachusetts.
Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to mild cognitive function.
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced upcoming oral and poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (“AD/PD™ 2026”), taking place March 17-21, 2026, in Copenhagen, Denmark and virtually.
Profitability This table compares NKGen Biotech and SQZ Biotechnologies' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% SQZ Biotechnologies -369.96% -119.83% -59.90% Valuation and Earnings This table compares NKGen Biotech and SQZ Biotechnologies"s revenue, earnings per share and valuation. Gross Revenue
Profitability This table compares SQZ Biotechnologies and NKGen Biotech's net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets SQZ Biotechnologies -369.96% -119.83% -59.90% NKGen Biotech N/A N/A -479.36% Valuation and Earnings This table compares SQZ Biotechnologies and NKGen Biotech"s top-line revenue, earnings per share (EPS) and valuation.